Clinical Trial Update: Efgartigimod in IVIG Dependent Myasthenia Gravis Patients [Phase 3]

View source ↗

Summary

Phase 3 trial of efgartigimod in intravenous immunoglobulin-dependent myasthenia gravis patients is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myasthenia Gravis

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: Clinique Neuro-Outaouais | Conditions: Myasthaenia Gravis | Phase 3 | Status: RECRUITING